Cargando…

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia

The downregulation of the glutamate system may be involved in positive, negative, and cognitive symptoms of schizophrenia. Through enhanced glutamate signaling, the activation of the α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid (AMPA) receptor, an ionotropic glutamate receptor, could be a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Maiko, Kunugi, Akiyoshi, Suzuki, Atsushi, Suzuki, Noriko, Suzuki, Motohisa, Kimura, Haruhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507438/ https://www.ncbi.nlm.nih.gov/pubmed/31086673 http://dx.doi.org/10.1002/prp2.479

Ejemplares similares

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

TAK-071, a muscarinic M(1) receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
por: Kurimoto, Emi, et al.
Publicado: (2019)

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015)

Transgenic mice overexpressing miR-137 in the brain show schizophrenia-associated behavioral deficits and transcriptome profiles
por: Arakawa, Yuuichi, et al.
Publicado: (2019)

Contribution of Hypothermia and CB(1) Receptor Activation to Protective Effects of TAK-937, a Cannabinoid Receptor Agonist, in Rat Transient MCAO Model
por: Suzuki, Noriko, et al.
Publicado: (2012)

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models
por: Baba, Rina, et al.
Publicado: (2021)

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017)

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

TAK1 Mediates ROS Generation Triggered by the Specific Cephalosporins through Noncanonical Mechanisms
por: Suzuki, Midori, et al.
Publicado: (2020)

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
por: Suzuki, Hiroyoshi, et al.
Publicado: (2019)

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
por: Evans, Rebecca, et al.
Publicado: (2022)

Effects of litter feeders on the transfer of (137)Cs to plants
por: Ishii, Nobuyoshi, et al.
Publicado: (2018)

Transcriptional targets of the schizophrenia risk gene MIR137
por: Collins, A L, et al.
Publicado: (2014)

miR-137: A New Player in Schizophrenia
por: Yin, Jingwen, et al.
Publicado: (2014)

AMPA receptors in the synapse turnover by monomer diffusion
por: Morise, Jyoji, et al.
Publicado: (2019)

Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia
por: Wright, C, et al.
Publicado: (2016)

Potential Impact of miR-137 and Its Targets in Schizophrenia
por: Wright, Carrie, et al.
Publicado: (2013)

TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma
por: Campolo, Michela, et al.
Publicado: (2020)

Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents
por: Harada, Akina, et al.
Publicado: (2019)

Characterization of a REST-Regulated Internal Promoter in the Schizophrenia Genome-Wide Associated Gene MIR137
por: Warburton, Alix, et al.
Publicado: (2015)

Therapeutic potential of AMPA receptor antagonist perampanel against cerebral ischemia: beyond epileptic disorder
por: Suda, Satoshi, et al.
Publicado: (2019)

Molecular Characterization of AMPA-Receptor-Containing Vesicles
por: Peters, John Jacob, et al.
Publicado: (2021)

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
por: Tang, Lanlan, et al.
Publicado: (2022)

MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER
por: Takahashi, Hidekazu, et al.
Publicado: (2015)

Biological proliferation of cesium-137 through the detrital food chain in a forest ecosystem in Japan
por: Murakami, Masashi, et al.
Publicado: (2014)

Internal organ dose rate conversion coefficients of Japanese macaques to (134)Cs,(137)Cs and (131)I(†)
por: Takamura, Yuta, et al.
Publicado: (2023)

Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

Correction to: Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

The schizophrenia risk gene product miR-137 alters presynaptic plasticity
por: Siegert, Sandra, et al.
Publicado: (2015)

Association of MIR137 With Symptom Severity and Cognitive Functioning in Belarusian Schizophrenia Patients
por: Kandratsenka, Hanna, et al.
Publicado: (2018)

Novel brain expressed RNA identified at the MIR137 schizophrenia-associated locus
por: Gianfrancesco, Olympia, et al.
Publicado: (2017)

Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis
por: Gleichman, Amy J, et al.
Publicado: (2014)

Post-Translational Modifications of the TAK1-TAB Complex
por: Hirata, Yusuke, et al.
Publicado: (2017)

Hybrid predictor for ground-motion intensity with machine learning and conventional ground motion prediction equation
por: Kubo, Hisahiko, et al.
Publicado: (2020)

Ampa Receptor Subunit Expression in the Endoplasmic Reticulum in Frontal Cortex of Elderly Patients with Schizophrenia
por: Hammond, John C., et al.
Publicado: (2012)

T166. VISUALIZATION OF AMPA RECEPTORS IN PATIENTS WITH SCHIZOPHRENIA AND DEPRESSION: THE FIRST PET IMAGING STUDY
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pachpf205ngit574ra7soagk75